Skip to main content

Table 1 Nonsusceptibility phenotypes by prior antibiotic exposure

From: Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infections

Pathogen

Nonsusceptibility phenotype

Overall, % NS (n/N)

Prior antibiotic exposure

0

1

≥2

Escherichia coli (n = 3013)a,b

Fluoroquinolone-NS

25.4 (758/2990)

25.5 (482/1888)

24.8 (253/1020)

28.0 (23/82)

Third-generation cephalosporin-NS

3.5 (105/3013)

3.8 (72/1903)

2.7 (28/1028)

6.1 (5/82)

MDR

23.4 (705/3013)

24.1 (458/1903)

21.6 (222/1028)

30.5 (25/82)

Carbapenem-NS

0.1 (4/3006)

0.2 (3/1900)

0.1 (1/1025)

0 (0/81)

Piperacillin/tazobactam-NS

4.4 (131/2965)

4.6 (86/1871)

4.1 (42/1014)

3.8 (3/80)

Klebsiella pneumoniae (n = 1039)a,c

Fluoroquinolone-NS

6.8 (70/1036)

6.0 (41/689)

7.5 (24/320)

18.5 (5/27)

Third-generation cephalosporin-NS

3.7 (38/1039)

2.7 (19/692)

5.0 (16/320)

11.1 (3/27)

MDR

10.1 (105/1039)

9.2 (64/692)

11.3 (36/320)

18.5(5/27)

Carbapenem-NS

1.5 (16/1035)

1.0 (7/690)

2.5 (8/319)

3.8 (1/26)

Piperacillin/tazobactam-NS

7.1 (73/1021)

6.0 (41/685)

9.4 (29/310)

11.5 (3/26)

Pseudomonas aeruginosa (n = 502)a,d

Fluoroquinolone-NS

21.8 (109/499)

22.2 (70/316)

20.6 (33/160)

26.1 (6/23)

Third-generation cephalosporin-NS

8.8 (44/502)

10.4 (33/318)

5.0 (8/161)

13.0 (3/23)

MDR

8.8 (44/502)

10.4 (33/318)

5.0 (8/161)

13.0 (3/23)

Carbapenem-NS

7.3 (36/496)

7.3 (23/314)

5.7 (9/159)

17.4 (4/23)

Piperacillin/tazobactam-NS

4.0 (20/494)

4.1 (13/314)

4.4 (7/158)

0 (0/22)

Other Enterobacteriaceae (n = 1539)a,e

Fluoroquinolone-NS

14.1 (216/1531)

14.5 (137/947)

13.9 (74/534)

10.0 (5/50)

Third-generation cephalosporin-NS

3.9 (60/1539)

4.0 (38/953)

3.9 (21/536)

2.0 (1/50)

MDR

27.6 (424/1539)

26.4 (252/953)

29.9 (160/536)

24.0 (12/50)

Carbapenem-NS

1.5 (23/1525)

1.5 (14/944)

1.7 (9/532)

0 (0/49)

Piperacillin/tazobactam-NS

4.9 (75/1529)

4.8 (45/947)

5.4 (29/533)

2.0 (1/49)

  1. MDR multidrug resistant, n number of nonsusceptible isolates, N total number of isolates, NS nonsusceptible
  2. aFor patients with missing susceptibility data, isolates were considered to be carbapenem-susceptible, piperacillin/tazobactam-susceptible, or non-MDR if they were susceptible to a third-generation cephalosporin. Otherwise, carbapenem, piperacillin/tazobactam, and MDR susceptibility data were considered missing, and isolates were not included in the analyses
  3. b E. coli: 903 isolates were missing carbapenem susceptibility data, of which 896 were classified according to the rules described above and seven were excluded from the analysis due to missing data; 1412 isolates were missing piperacillin/tazobactam susceptibility data, of which 1364 were classified according to the rules and 48 were excluded
  4. c K. pneumoniae: 317 isolates were missing carbapenem susceptibility data, of which 313 were classified according to the rules and four were excluded; 443 isolates were missing piperacillin/tazobactam susceptibility data, of which 425 were classified according to the rules and 18 were excluded
  5. d P. aeruginosa: 97 isolates were missing carbapenem susceptibility data, of which 91 were classified according to the rules and six were excluded; 109 isolates were missing piperacillin/tazobactam susceptibility data, of which 101 were classified according to the rules and eight were excluded
  6. eOther Enterobacteriaceae: 494 isolates were missing carbapenem susceptibility data, of which 480 were classified according to the rules and 14 were excluded; 721 isolates were missing piperacillin/tazobactam susceptibility data, of which 711 were classified according to the rules and ten were excluded